Thoughts on Afami-cel’s Promising Clinical and Translational Data for SS and MRCLS; Adaptimmune’s Ph2 SPEARHEAD-1 Trial on Track to Meet Its Primary Endpoint by YE 2021
On Thursday, November 11, Adaptimmune reported (press release) updated clinical and translational data from afami-cel’s (MAGE-A4 SPEAR-T; formerly ADP-A2M4) Ph2 SPEARHEAD-1 trial for advanced synovial sarcoma (SS) and myxoid / round cell liposarcoma (MRCLS) at CTOS 2021. Below, Celltelligence provides insights on Adaptimmune’s CMC preparations ahead of afami-cel’s BLA filing, while discussing how afami-cel compares to GSK’s lete-cel (NY-ESO-1 TCR-T) in MRCLS.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.